A phase 2 trial assessing ALG 097558
Latest Information Update: 16 Mar 2024
At a glance
- Drugs ALG-097558 (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 12 Mar 2024 According to Aligos Therapeutics media release, Phase 2 enabling activities are underway with financial support from the National Institute of Allergy and Infectious Diseases (NIAID).
- 02 Nov 2023 According to Aligos Therapeutics media release, the NIAID awarded Aligos an $8.5M contract to conduct Phase 2 enabling activities, which includes multiple nonclinical and clinical studies. These studies will be initiated in H1 2024 and topline data are expected in H2 2025.
- 15 Feb 2023 New trial record